Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma.

Detalhes bibliográficos
Autor(a) principal: Magalhães, Giselle Santos
Data de Publicação: 2021
Outros Autores: Gregório, Juliana Fabiana, Ribeiro, Arthur Tonani Pereira Cançado, Baroni, Isis Felippe, Vasconcellos, Ana Victoria de Oliveira, Nakashima, Gabriela Pansanato, Oliveira, Isabel Fusaro Aguiar, Matos, Natália Alves de, Castro, Thalles de Freitas, Bezerra, Frank Silva, Sinisterra, Ruben Dario, Pinho, Vanessa, Teixeira, Mauro Martins, Santos, Robson Augusto Souza dos, Machado, Maria da Glória Rodrigues, Santos, Maria José Campagnole dos
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFOP
Texto Completo: http://www.repositorio.ufop.br/jspui/handle/123456789/14035
Resumo: The presence of eosinophils and neutrophils in the lungs of asthmatic patients is associated with the severity of the disease and resistance to corticosteroids. Thus, defective resolution of eosinophilic and neutrophilic inflammation is importantly related to exacerbation of asthma. In this study, we investigated a therapeutic action of angiotensin-(1-7) (Ang-(1-7)) in a model of asthma induced by ovalbumin (OVA) and lipopolysaccharide (LPS). Balb-c mice were sensitized and challenged with OVA. Twentythree hours after the last OVA challenge, experimental groups received LPS, and 1 h and 7 h later, mice were treated with oral formulation of Ang-(1-7). On the next day, 45 h after the last challenge with OVA, mice were subjected to a test of motor and exploratory behavior; 3 h later, lung function was evaluated, and bronchoalveolar lavage fluid (BALF) and lungs were collected. Motor and exploratory activities were lower in OVA + LPSchallenged mice. Treatment with Ang-(1-7) improved these behaviors, normalized lung function, and reduced eosinophil, neutrophil, myeloperoxidase (MPO), eosinophilic peroxidase (EPO), and ERK1/2 phosphorylation (p-ERK1/2) in the lungs. In addition, Ang-(1-7) decreased the deposition of mucus and extracellular matrix in the airways. These results extended those of previous studies by demonstrating that oral administration of Ang-(1-7) at the peak of pulmonary inflammation can be valuable for the treatment of neutrophil- and eosinophil-mediated asthma. Therefore, these findings potentially provide a new drug to reverse the natural history of the disease, unlike the current standards of care that manage the disease symptoms at best.
id UFOP_ea94c55a939ce34ea598622c16213f5e
oai_identifier_str oai:repositorio.ufop.br:123456789/14035
network_acronym_str UFOP
network_name_str Repositório Institucional da UFOP
repository_id_str 3233
spelling Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma.Resolution of inflammationAllergic lung inflammationLipopolysaccharide(LPS)The presence of eosinophils and neutrophils in the lungs of asthmatic patients is associated with the severity of the disease and resistance to corticosteroids. Thus, defective resolution of eosinophilic and neutrophilic inflammation is importantly related to exacerbation of asthma. In this study, we investigated a therapeutic action of angiotensin-(1-7) (Ang-(1-7)) in a model of asthma induced by ovalbumin (OVA) and lipopolysaccharide (LPS). Balb-c mice were sensitized and challenged with OVA. Twentythree hours after the last OVA challenge, experimental groups received LPS, and 1 h and 7 h later, mice were treated with oral formulation of Ang-(1-7). On the next day, 45 h after the last challenge with OVA, mice were subjected to a test of motor and exploratory behavior; 3 h later, lung function was evaluated, and bronchoalveolar lavage fluid (BALF) and lungs were collected. Motor and exploratory activities were lower in OVA + LPSchallenged mice. Treatment with Ang-(1-7) improved these behaviors, normalized lung function, and reduced eosinophil, neutrophil, myeloperoxidase (MPO), eosinophilic peroxidase (EPO), and ERK1/2 phosphorylation (p-ERK1/2) in the lungs. In addition, Ang-(1-7) decreased the deposition of mucus and extracellular matrix in the airways. These results extended those of previous studies by demonstrating that oral administration of Ang-(1-7) at the peak of pulmonary inflammation can be valuable for the treatment of neutrophil- and eosinophil-mediated asthma. Therefore, these findings potentially provide a new drug to reverse the natural history of the disease, unlike the current standards of care that manage the disease symptoms at best.2021-11-24T20:15:57Z2021-11-24T20:15:57Z2021info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfMAGALHÃES, G. S. et al. Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma. Frontiers in Pharmacology, v. 12, p. 1-9, mar. 2021. Disponível em: <https://www.frontiersin.org/articles/10.3389/fphar.2021.557962/full>. Acesso em: 10 jun. 2021.1663-9812http://www.repositorio.ufop.br/jspui/handle/123456789/14035 https://doi.org/10.3389/fphar.2021.557962This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Source: The article PDF.info:eu-repo/semantics/openAccessMagalhães, Giselle SantosGregório, Juliana FabianaRibeiro, Arthur Tonani Pereira CançadoBaroni, Isis FelippeVasconcellos, Ana Victoria de OliveiraNakashima, Gabriela PansanatoOliveira, Isabel Fusaro AguiarMatos, Natália Alves deCastro, Thalles de FreitasBezerra, Frank SilvaSinisterra, Ruben DarioPinho, VanessaTeixeira, Mauro MartinsSantos, Robson Augusto Souza dosMachado, Maria da Glória RodriguesSantos, Maria José Campagnole dosengreponame:Repositório Institucional da UFOPinstname:Universidade Federal de Ouro Preto (UFOP)instacron:UFOP2021-11-24T20:16:06Zoai:repositorio.ufop.br:123456789/14035Repositório InstitucionalPUBhttp://www.repositorio.ufop.br/oai/requestrepositorio@ufop.edu.bropendoar:32332021-11-24T20:16:06Repositório Institucional da UFOP - Universidade Federal de Ouro Preto (UFOP)false
dc.title.none.fl_str_mv Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma.
title Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma.
spellingShingle Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma.
Magalhães, Giselle Santos
Resolution of inflammation
Allergic lung inflammation
Lipopolysaccharide(LPS)
title_short Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma.
title_full Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma.
title_fullStr Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma.
title_full_unstemmed Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma.
title_sort Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma.
author Magalhães, Giselle Santos
author_facet Magalhães, Giselle Santos
Gregório, Juliana Fabiana
Ribeiro, Arthur Tonani Pereira Cançado
Baroni, Isis Felippe
Vasconcellos, Ana Victoria de Oliveira
Nakashima, Gabriela Pansanato
Oliveira, Isabel Fusaro Aguiar
Matos, Natália Alves de
Castro, Thalles de Freitas
Bezerra, Frank Silva
Sinisterra, Ruben Dario
Pinho, Vanessa
Teixeira, Mauro Martins
Santos, Robson Augusto Souza dos
Machado, Maria da Glória Rodrigues
Santos, Maria José Campagnole dos
author_role author
author2 Gregório, Juliana Fabiana
Ribeiro, Arthur Tonani Pereira Cançado
Baroni, Isis Felippe
Vasconcellos, Ana Victoria de Oliveira
Nakashima, Gabriela Pansanato
Oliveira, Isabel Fusaro Aguiar
Matos, Natália Alves de
Castro, Thalles de Freitas
Bezerra, Frank Silva
Sinisterra, Ruben Dario
Pinho, Vanessa
Teixeira, Mauro Martins
Santos, Robson Augusto Souza dos
Machado, Maria da Glória Rodrigues
Santos, Maria José Campagnole dos
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Magalhães, Giselle Santos
Gregório, Juliana Fabiana
Ribeiro, Arthur Tonani Pereira Cançado
Baroni, Isis Felippe
Vasconcellos, Ana Victoria de Oliveira
Nakashima, Gabriela Pansanato
Oliveira, Isabel Fusaro Aguiar
Matos, Natália Alves de
Castro, Thalles de Freitas
Bezerra, Frank Silva
Sinisterra, Ruben Dario
Pinho, Vanessa
Teixeira, Mauro Martins
Santos, Robson Augusto Souza dos
Machado, Maria da Glória Rodrigues
Santos, Maria José Campagnole dos
dc.subject.por.fl_str_mv Resolution of inflammation
Allergic lung inflammation
Lipopolysaccharide(LPS)
topic Resolution of inflammation
Allergic lung inflammation
Lipopolysaccharide(LPS)
description The presence of eosinophils and neutrophils in the lungs of asthmatic patients is associated with the severity of the disease and resistance to corticosteroids. Thus, defective resolution of eosinophilic and neutrophilic inflammation is importantly related to exacerbation of asthma. In this study, we investigated a therapeutic action of angiotensin-(1-7) (Ang-(1-7)) in a model of asthma induced by ovalbumin (OVA) and lipopolysaccharide (LPS). Balb-c mice were sensitized and challenged with OVA. Twentythree hours after the last OVA challenge, experimental groups received LPS, and 1 h and 7 h later, mice were treated with oral formulation of Ang-(1-7). On the next day, 45 h after the last challenge with OVA, mice were subjected to a test of motor and exploratory behavior; 3 h later, lung function was evaluated, and bronchoalveolar lavage fluid (BALF) and lungs were collected. Motor and exploratory activities were lower in OVA + LPSchallenged mice. Treatment with Ang-(1-7) improved these behaviors, normalized lung function, and reduced eosinophil, neutrophil, myeloperoxidase (MPO), eosinophilic peroxidase (EPO), and ERK1/2 phosphorylation (p-ERK1/2) in the lungs. In addition, Ang-(1-7) decreased the deposition of mucus and extracellular matrix in the airways. These results extended those of previous studies by demonstrating that oral administration of Ang-(1-7) at the peak of pulmonary inflammation can be valuable for the treatment of neutrophil- and eosinophil-mediated asthma. Therefore, these findings potentially provide a new drug to reverse the natural history of the disease, unlike the current standards of care that manage the disease symptoms at best.
publishDate 2021
dc.date.none.fl_str_mv 2021-11-24T20:15:57Z
2021-11-24T20:15:57Z
2021
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv MAGALHÃES, G. S. et al. Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma. Frontiers in Pharmacology, v. 12, p. 1-9, mar. 2021. Disponível em: <https://www.frontiersin.org/articles/10.3389/fphar.2021.557962/full>. Acesso em: 10 jun. 2021.
1663-9812
http://www.repositorio.ufop.br/jspui/handle/123456789/14035
 https://doi.org/10.3389/fphar.2021.557962
identifier_str_mv MAGALHÃES, G. S. et al. Oral formulation of Angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and meutrophilic asthma. Frontiers in Pharmacology, v. 12, p. 1-9, mar. 2021. Disponível em: <https://www.frontiersin.org/articles/10.3389/fphar.2021.557962/full>. Acesso em: 10 jun. 2021.
1663-9812
 https://doi.org/10.3389/fphar.2021.557962
url http://www.repositorio.ufop.br/jspui/handle/123456789/14035
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFOP
instname:Universidade Federal de Ouro Preto (UFOP)
instacron:UFOP
instname_str Universidade Federal de Ouro Preto (UFOP)
instacron_str UFOP
institution UFOP
reponame_str Repositório Institucional da UFOP
collection Repositório Institucional da UFOP
repository.name.fl_str_mv Repositório Institucional da UFOP - Universidade Federal de Ouro Preto (UFOP)
repository.mail.fl_str_mv repositorio@ufop.edu.br
_version_ 1813002816830046208